GeneNova

For safer, more efficacious and accessible AAV gene therapy

Our vision is to innovate AAV bioproduction and provide a platform aimed at order of magnitudes improvement compared to state-of-art today. We do this by combining expertise from experts of different areas aligning world-leading Swedish faculty within cellbiology, pharmacology, systems biology, neurology, drug discovery, industrial biotechnology, and mathematics with Swedish global commercial technology, service providers and biopharmaceutical companies to one goal – to enable the sustainable access to curative treatment by AAV for the patient.

GeneNova is funded by partner companies and VINNOVA Sweden’s innovation agency 2021–2026.

Coordinator: KTH Royal Inst Technology.

PROJECTS